Matthew W Foehr - Net Worth and Insider Trading

Matthew W Foehr Net Worth

The estimated net worth of Matthew W Foehr is at least $33 Million dollars as of 2024-04-26. Matthew W Foehr is the President and CEO of OmniAb Inc and owns about 2,908,803 shares of OmniAb Inc (OABI) stock worth over $13 Million. Matthew W Foehr is the President and COO of Ligand Pharmaceuticals Inc and owns about 173,354 shares of Ligand Pharmaceuticals Inc (LGND) stock worth over $12 Million. Matthew W Foehr is also the Director of Viking Therapeutics Inc and owns about 111,250 shares of Viking Therapeutics Inc (VKTX) stock worth over $8 Million. Besides these, Matthew W Foehr also holds Ritter Pharmaceuticals Inc (RTTR) , China Teletech Holding Inc (CNCT) . Details can be seen in Matthew W Foehr's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Matthew W Foehr has not made any transactions after 2024-03-22 and currently still holds the listed stock(s).

Transaction Summary of Matthew W Foehr

To

Matthew W Foehr Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Matthew W Foehr owns 6 companies in total, including Ligand Pharmaceuticals Inc (LGND) , Viking Therapeutics Inc (VKTX) , and Ritter Pharmaceuticals Inc (RTTR) among others .

Click here to see the complete history of Matthew W Foehr’s form 4 insider trades.

Insider Ownership Summary of Matthew W Foehr

Ticker Comapny Transaction Date Type of Owner
LGND Ligand Pharmaceuticals Inc 2022-05-13 EVP and COO
VKTX Viking Therapeutics Inc 2022-05-02 director
RTTR Ritter Pharmaceuticals Inc 2020-01-21 director
QLGN Qualigen Therapeutics Inc 2015-06-24 director
AHPA Avista Public Acquisition Corp II 2022-11-01 director & President & CEO
OABI OmniAb Inc 2024-03-22 director & President & CEO

Matthew W Foehr Latest Holdings Summary

Matthew W Foehr currently owns a total of 5 stocks. Among these stocks, Matthew W Foehr owns 2,908,803 shares of OmniAb Inc (OABI) as of March 22, 2024, with a value of $13 Million and a weighting of 39.1%. Matthew W Foehr owns 173,354 shares of Ligand Pharmaceuticals Inc (LGND) as of May 13, 2022, with a value of $12 Million and a weighting of 37.67%. Matthew W Foehr also owns 111,250 shares of Viking Therapeutics Inc (VKTX) as of May 2, 2022, with a value of $8 Million and a weighting of 23.23%. The other 2 stocks Ritter Pharmaceuticals Inc (RTTR) , China Teletech Holding Inc (CNCT) have a combined weighting of 0% among all his current holdings.

Latest Holdings of Matthew W Foehr

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
OABI OmniAb Inc 2024-03-22 2,908,803 4.42 12,856,909
LGND Ligand Pharmaceuticals Inc 2022-05-13 173,354 71.45 12,386,143
VKTX Viking Therapeutics Inc 2022-05-02 111,250 68.65 7,637,313
RTTR Ritter Pharmaceuticals Inc 2018-08-17 2,190 0.45 986
CNCT China Teletech Holding Inc 2003-05-14 14 0.00 0

Holding Weightings of Matthew W Foehr


Matthew W Foehr Form 4 Trading Tracker

According to the SEC Form 4 filings, Matthew W Foehr has made a total of 9 transactions in OmniAb Inc (OABI) over the past 5 years, including 9 buys and 0 sells. The most-recent trade in OmniAb Inc is the acquisition of 225,000 shares on March 22, 2024, which cost Matthew W Foehr around $1 Million.

According to the SEC Form 4 filings, Matthew W Foehr has made a total of 7 transactions in Ligand Pharmaceuticals Inc (LGND) over the past 5 years, including 1 buys and 6 sells. The most-recent trade in Ligand Pharmaceuticals Inc is the acquisition of 2,500 shares on May 13, 2022, which cost Matthew W Foehr around $206,900.

According to the SEC Form 4 filings, Matthew W Foehr has made a total of 3 transactions in Viking Therapeutics Inc (VKTX) over the past 5 years, including 2 buys and 1 sells. The most-recent trade in Viking Therapeutics Inc is the acquisition of 45,000 shares on May 2, 2022, which cost Matthew W Foehr around $111,150.

More details on Matthew W Foehr's insider transactions can be found in the Insider Trading History of Matthew W Foehr table.

Insider Trading History of Matthew W Foehr

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Matthew W Foehr Trading Performance

GuruFocus tracks the stock performance after each of Matthew W Foehr's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Matthew W Foehr is 3.95%. GuruFocus also compares Matthew W Foehr's trading performance to market benchmark return within the same time period. The performance of stocks bought by Matthew W Foehr within 3 months outperforms 13 times out of 24 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Matthew W Foehr's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Matthew W Foehr

Average Return

61.87%

Average return per transaction

Outperforming Transactions

68%

13 out of 19 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 1.6 3.95 5.66 61.87 36.82 18.96
Relative Return to S&P 500(%) 0.73 0.73 0.01 53.03 26.83 9.31

Matthew W Foehr Ownership Network

Ownership Network List of Matthew W Foehr

No Data

Ownership Network Relation of Matthew W Foehr


Matthew W Foehr Owned Company Details

What does Ligand Pharmaceuticals Inc do?

Who are the key executives at Ligand Pharmaceuticals Inc?

Matthew W Foehr is the EVP and COO of Ligand Pharmaceuticals Inc. Other key executives at Ligand Pharmaceuticals Inc include Chief Financial Officer Octavio Espinoza , CHIEF LEGAL OFFICER & Andrew Reardon , and CEO & President John L Higgins .

Ligand Pharmaceuticals Inc (LGND) Insider Trades Summary

Over the past 18 months, Matthew W Foehr made no insider transaction in Ligand Pharmaceuticals Inc (LGND). Other recent insider transactions involving Ligand Pharmaceuticals Inc (LGND) include a net sale of 20,000 shares made by John L Higgins , a net sale of 10,852 shares made by John W Kozarich , and a net sale of 8,301 shares made by Stephen L Sabba .

In summary, during the past 3 months, insiders sold 2,033 shares of Ligand Pharmaceuticals Inc (LGND) in total and bought 0 shares, with a net sale of 2,033 shares. During the past 18 months, 41,289 shares of Ligand Pharmaceuticals Inc (LGND) were sold and 4,000 shares were bought by its insiders, resulting in a net sale of 37,289 shares.

Ligand Pharmaceuticals Inc (LGND)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Ligand Pharmaceuticals Inc Insider Transactions

No Available Data

Matthew W Foehr Mailing Address

Above is the net worth, insider trading, and ownership report for Matthew W Foehr. You might contact Matthew W Foehr via mailing address: 11119 North Torrey Pines Rd #200, La Jolla Ca 92037.

Discussions on Matthew W Foehr

No discussions yet.